Novartis – Talk Bio

Novartis antibody ianalumab helps prolong control of rare blood disorder ITP

6 hours ago talkbio0Tagged Antibodies, Asymmetric Septal Hypertrophy, Autoimmune thrombocytopenia, disorder control (procedure), eltrombopag, ianalumab, Inosine Triphosphate, ITP, Novartis, Promacta, rare blood disorder, treatment failure, VAYHIT2 trial

Novartis; ianalumab; primary immune thrombocytopenia; ITP; rare blood disorder; antibody; VAYHIT2 trial; time to treatment failure; disease control; ASH 2025; Promacta; eltrombopag

Novartis and Relation Therapeutics form AI-driven, multi-program atopic disease collaboration

1 day ago talkbio0Tagged * * atopic diseases * *, * * functional cell, AI-powered, Asthma, atlases, Billion, Drug Discovery, Eczema, Hypersensitivity, IL13 gene, immuno-dermatology, Lab-in-the-Loop, milestones, multi-program collaboration, Novartis

Novartis; Relation Therapeutics; AI-powered drug discovery; Lab-in-the-Loop; atopic diseases; immuno-dermatology; multi-program collaboration; asthma; allergies; eczema; allergic rhinitis; $55 million upfront; $1.7 billion milestones; functional cell atlases

Biotech interest shifting from obesity ‘halo’ to other areas like oncology and blood cancers

2 days ago talkbio0Tagged Autoimmune, biotech pivot, Halo brace, Investments, leukemia, Neoplasms, Novartis, Obesity, sector rotation

obesity drugs; biotech pivot; investment trends; Novartis; leukemia; obesity halo; sector rotation; autoimmune; oncology

Whitehawk Therapeutics Appoints Margaret Dugan as Chief Medical Officer

1 week ago talkbio0Tagged Chief Medical Officer, Chronic multifocal osteomyelitis, Clinical Trials, Dracen Pharmaceuticals, Drug Development, Margaret Dugan, Neoplasms, Novartis, Schrödinger, therapeutic autologous dendritic cells, Whitehawk Therapeutics

Whitehawk Therapeutics; Margaret Dugan; Chief Medical Officer; CMO; oncology; ADC; drug development; clinical trials; Novartis; Dracen Pharmaceuticals; Schrödinger

Novartis Announces Plans to Lay Off 550 Workers at Swiss Factory

2 weeks ago talkbio0Tagged Investments, layoffs, Novartis, pharmaceutical manufacturing, restructuring, Schweizerhalle, Stein facility, Switzerland

Novartis; layoffs; Switzerland; Stein facility; pharmaceutical manufacturing; restructuring; Schweizerhalle investment

FDA Approves Novartis’ Itvisma: Expanding Gene Therapy to Older Spinal Muscular Atrophy Patients

2 weeks ago talkbio0Tagged Adult, Approved, gene therapy, intrathecal formulation, Itvisma, Novartis, older children, Spinal Muscular Atrophy, United States Food and Drug Administration, Zolgensma

Novartis; FDA approval; Itvisma; Zolgensma; Spinal Muscular Atrophy (SMA); Gene Therapy; Older Children; Adults; Intrathecal Formulation

ASH 2025: Breakthroughs in In Vivo CAR-T Data from Kelonia; Phase 3 Wins for Lilly, J&J, and Novartis

2 weeks ago talkbio0Tagged 2025, Asymmetric Septal Hypertrophy, CAR-T, CAR-T therapy, Eli Lilly, in vivo, Kelonia Therapeutics, Multiple Myeloma, Novartis, Phase 3 trials

ASH 2025; in vivo CAR-T; Kelonia Therapeutics; KLN-1010; multiple myeloma; Johnson & Johnson; Lilly; Novartis; CAR-T therapy; Phase 3 trials

Novartis Raises Sales Targets for Key Cancer Drugs, Tweaks Yearly Growth Guidance

3 weeks ago talkbio0Tagged cancer drugs, Drug Industry, Kisqali, leukemia, Malignant neoplasm of breast, Novartis, peak sales, Pluvicto, sales guidance, Scemblix

Novartis; Kisqali; Scemblix; Pluvicto; sales guidance; peak sales forecast; cancer drugs; breast cancer; leukemia; pharmaceutical industry

Novartis CEO on $12B Avidity Deal: ‘Could Have Been Twice as Big’

1 month ago talkbio0Tagged Acquisition, Avidity Biosciences, financial outlook, growth strategy, Merger, Neuromuscular Diseases, Novartis, RNA, SpinCo ', Vas Narasimhan

Novartis; Avidity Biosciences; Vas Narasimhan; merger; acquisition; biotech; RNA therapeutics; $12 billion deal; neuromuscular diseases; SpinCo; financial outlook; growth strategy

Novartis to Acquire RNA Drugmaker Avidity Biosciences in $12 Billion Deal

1 month ago talkbio0Tagged 2026, Acquisition, AOC, Avidity Biosciences, Closed, Muscular Dystrophy, Duchenne, Muscular Dystrophy, Facioscapulohumeral, MYOTONIC DYSTROPHY 1, Neuromuscular Diseases, Novartis, Platform, RNA therapeutics, SpinCo ', xRNA

Novartis; Avidity Biosciences; acquisition; RNA therapeutics; neuromuscular diseases; Duchenne muscular dystrophy; myotonic dystrophy type 1; facioscapulohumeral muscular dystrophy; AOC platform; SpinCo; biotech; xRNA strategy; 2026 closing